Ind-Swift Laboratories Ltd
INDSWFTLAB
Company Profile
Business description
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
Contact
SCO 850, NAC
Shivalik Enclave
Manimajra
ChandigarhPB160101
INDT: +91 1725061850
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
1,246
Stocks News & Analysis
stocks
Hostile takeover on the cards for this ASX income opportunity
IFM lobs reasonable takeover offer.
stocks
Get ready for major US tech earnings starting tomorrow morning
Microsoft, Amazon, Alphabet, and Meta will all release quarterly earnings. Here’s what analysts are looking for.
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.70 | 16.00 | 0.18% |
| CAC 40 | 8,072.13 | 31.96 | -0.39% |
| DAX 40 | 23,954.56 | 63.70 | -0.27% |
| Dow JONES (US) | 48,883.34 | 258.59 | -0.53% |
| FTSE 100 | 10,213.11 | 119.68 | -1.16% |
| HKSE | 26,111.84 | 432.06 | 1.68% |
| NASDAQ | 24,652.93 | 10.87 | -0.04% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,770.30 | 5.90 | 0.05% |
| S&P 500 | 7,133.28 | 5.52 | -0.08% |
| S&P/ASX 200 | 8,687.00 | 9.40 | 0.11% |
| SSE Composite Index | 4,107.51 | 28.88 | 0.71% |